Drospirenone/ethinyl Estradiol/levomefolate Calcium And Levomefolate Calcium Kit
Product Images NDC 0781-4103
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Drospirenone/ethinyl Estradiol/levomefolate Calcium And Levomefolate Calcium (NDC 0781-4103). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Sandoz Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Fig 1 (Image 02)
Fig 2 (Image 03)
This text provides ranges of the number of women with a blood clot per 10,000 women years, categorized by Non-Pregnant and Postpartum stages and usage of combined oral contraceptives. The Non-Pregnant stage is further divided into Non-COC users and COC users. Actual duration of pregnancy in the reference studies was used for determining the clotting rate during Pregnancy. The number of women with a blood clot is represented on the y-axis and the associated ranges are represented on the x-axis.*
Chart (Image 04)
This appears to be descriptions of different methods of birth control, including the number of pregnancies per 100 women using each method. It lists various types of birth control such as injections, intrauterine devices, sterilization, birth control pills, and condoms. Additionally, it lists the effectiveness of certain methods for preventing pregnancy such as avoiding sex during the most fertile days of the monthly cycle and using spermicide. However, did not successfully capture all parts of the text, so some information may be missing.*
Blister (Image 05)
Graph (Image 06)
This appears to be a chart displaying different ranges for blood clot risk in non-pregnant women who either use or do not use COC (contraceptive pills), pregnant women, and women in the postpartum period (up to 12 weeks after birth). The numbers indicate the number of women out of 10,000 women years (WY) who experienced a blood clot. The pregnancy data is based on the actual duration of pregnancy in reference studies, with an assumption that the pregnancy takes nine months. The rate given is 7 to 27 per 10,000 WY.*
Fig 3 (Image 07)
Fig 4 (Image 08)
Fig 6 (Image 09)
This is a graph illustrating RBC folate levels in a group of 75 participants taking Yasmin with levomefolate calcium over the course of 44 weeks. The graph shows the baseline folate levels at the beginning of the study, followed by a decrease during the elimination phase, and then an increase during the treatment phase with time. The x-axis represents the 44-week timeline, and the y-axis represents the folate concentration measured in nm.*
Carton 3s (Image 10)
Fig 5 (Image 11)
This is a graph showing the levels of plasma folates measured in nmol/L over time (in weeks) for a group of 75 people. The graph includes three phases: baseline, treatment, and elimination. During the treatment phase, the group was given a combination of vasmin and levomefolate calcium. The graph shows that the plasma folate levels increased during treatment and decreased during the elimination phase.*
Image 12
This is a list of relevant studies related to breast cancer risk associated with the use of combined oral contraceptives. The studies include the NICHD Women's Care Study, French E3N cohort Study, Shanghai Women's Health Study, The Nurses’ Health Study II, Oxford Family Planning Study, and Danish Sex Hormone Register Study. Some of these studies compare breast cancer risk between women who have ever used COC versus those who have never used it, while others compare breast cancer risk between current COC users and those who have never used it. The table at the end provides effect estimates of the risk, such as odds ratio, relative risk, and hazard ratio, from some of the studies.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.